<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE319nnn/GSE319733/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type> Other</gds_type><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319733</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells</name><description>The presence of B cells in tumors is correlated with a positive prognosis in several types of cancers, including high-grade serous ovarian cancer (HGSOC). These cells give rise to plasma cells (PCs) that originate from germinal centers (GCs) and secrete tumor-reactive antibodies. GCs also give rise to memory B cells (MBCs); yet, it is unknown if tumor-reactive MBCs form in cancer patients. Single-cell RNA-seq revealed that retroperitoneal lymph nodes (LNs) located near the tumor, host primarily class-switched resting MBCs. Immunoglobulin sequencing, clonal analysis, and generation of monoclonal antibodies demonstrated that these MBCs carried tumor-reactive antibodies, some of which bind MMP14, an enzyme abundantly expressed by HGSOC tumors. Although tumor-associated retroperitoneal LNs did not exhibit an active immune response, tumor binding of the MBCs derived from these LNs was dependent on somatic hypermutations (SHM), suggesting that they originated from a previous GC reaction. Different and overlapping types of MBC subpopulations were detected in the primary tumor and associated patient-matched LNs, some of which show clonal relationships between the two sites. Thus, our study extends our understanding of the anti-tumor memory response by revealing an inter-organ link between tumor-reactive MBC clones in ovarian cancer patients, which could potentially be manipulated in ovarian cancer patients.</description><dates><publication>2026/05/26</publication></dates><accession>GSE319733</accession><cross_references><GSM>GSM9524785</GSM><GSM>GSM9524774</GSM><GSM>GSM9524773</GSM><GSM>GSM9524784</GSM><GSM>GSM9524776</GSM><GSM>GSM9524787</GSM><GSM>GSM9524775</GSM><GSM>GSM9524786</GSM><GSM>GSM9524781</GSM><GSM>GSM9524780</GSM><GSM>GSM9524783</GSM><GSM>GSM9524772</GSM><GSM>GSM9524782</GSM><GSM>GSM9524771</GSM><GSM>GSM9524778</GSM><GSM>GSM9524789</GSM><GSM>GSM9524788</GSM><GSM>GSM9524777</GSM><GSM>GSM9524779</GSM><GSM>GSM9524790</GSM><GPL>24676</GPL><GSE>319733</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>